OGOliver Gaemperli

Oliver Gaemperli

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Oliver Gaemperli has a total of 204 co-authors. Here are the top co-authors by number of shared publications:

  • Philipp A. Kaufmann

    Department of Nuclear Medicine, Cardiac Imaging, University Hospital Zurich, Ramistrasse 100, CH-8091 Zurich, Switzerland

    14 shared publications
  • Dominik C. Benz

    Department of Nuclear Medicine, Cardiac Imaging, University Hospital of Zurich, Ramistrasse 100, CH-8091, Zurich, Switzerland; Advanced Clinician Scientist Program, University Medicine Zurich (UMZH), Switzerland; Department of Cardiology, University Hospital of Zurich, Ramistrasse 100, CH-8091, Zurich, Switzerland

    7 shared publications
  • Philipp A. Kaufmann

    Department of Nuclear Medicine, Cardiac Imaging, University Hospital of Zurich, Ramistrasse 100, CH-8091, Zurich, Switzerland

    7 shared publications
  • Thomas F. Lüscher

    University Hospital Zürich

    7 shared publications
  • Hatem Alkadhi

    University Hospital Zürich

    6 shared publications
  • Ines Valenta

    Department of Medical Radiology and Cardiovascular Center, University Hospital Zurich, Raemistrasse 100, CH-8091 Zurich, Switzerland

    6 shared publications

Latest Publications

  • Open Access

    Non-invasive screening for coronary artery disease in asymptomatic diabetic patients: a systematic review and meta-analysis of randomised controlled trials

    by Olivier F Clerc, Tobias A Fuchs, Julia Stehli, Dominik C Benz, Christoph Gräni, Michael Messerli, Andreas A Giannopoulos, Ronny R Buechel, Thomas F Lüscher, Aju P Pazhenkottil, et al.

    It is unclear whether non-invasive screening of asymptomatic diabetic patients for coronary artery disease (CAD) may improve cardiac outcomes. Thus, we performed a systematic literature review and meta-analysis of randomised controlled trials (RCT’s) on this topic. We searched appropriate RCT’s in five online databases (PubMed/MEDLINE, Cochrane Library, Embase, Scopus, and Web of Science) from January 2000 to November 2017 and in 41 recent reviews. Two investigators independently extracted and assessed study data using standardised forms. Additional unpublished data were obtained from trial authors. The primary endpoint ‘any cardiac event’ was a composite of cardiac death, non-fatal myocardial infarction (MI), unstable angina (UA), or heart failure (HF) hospitalisation. We performed a meta-analysis of relative risks (RRs) with 95% confidence intervals (CI) using the Mantel–Haenszel method. We included five RCT’s with 3299 patients, of which 189 (5.7%) experienced any cardiac event on follow-up (weighted mean 4.1 years). Non-invasive CAD screening significantly reduced any cardiac event by 27% [RR 0.73 (95% CI 0.55–0.97), P = 0.028, number needed to screen 56]. This result was driven by important, albeit non-significant decreases in non-fatal MI [RR 0.65 (95% CI 0.41–1.02), P = 0.062] and HF hospitalisation [RR 0.61 (95% CI 0.33–1.10), P = 0.100]. Non-invasive CAD screening did not significantly affect cardiac death [RR 0.92 (95% CI 0.53–1.60), P = 0.77] and UA [RR 0.73 (95% CI 0.41–1.31), P = 0.29]. Compared with the standard care, non-invasive CAD screening reduced cardiac events by 27% in asymptomatic diabetic patients, largely through reductions in non-fatal MIs, and HF hospitalisations. The present results justify larger, appropriately powered trials to potentially revisit current recommendations.


  • Open Access

    Percutaneous pulmonary valve implantation in grown‐up congenital heart disease patients: Insights from the Zurich experience

    by Luca Oechslin, Roberto Corti, Matthias Greutmann, Oliver Kretschmar, Oliver Gaemperli

    Objectives: The aim of the study was to assess indications, procedural success, complications, echocardiographic, and clinical outcomes of percutaneous pulmonary valve implantation (PPVI) in adult patients with congenital heart disease (CHD).Background: PPVI offers a non‐surgical treatment option for failing prosthetic conduits in pulmonary position. However, efficacy and clinical outcomes after PPVI are still underreported.Methods: From January 2008 to March 2016, 25 adult CHD patients with right ventricular outflow tract (RVOT) stenosis and/or pulmonary regurgitation underwent PPVI in our institution. Clinical and echocardiographic data was collected at baseline, at 12 months of follow‐up and yearly afterwards.Results: Tetralogy of Fallot and repaired pulmonary atresia were among the most prevalent underlying congenital defects. Twenty‐one (84%) received a Medtronic Melody® and four (16%) patients an Edwards Sapien valve prosthesis. The PPVI procedure was successful in all 25 patients. Pre‐stenting was performed in all but two (8%) patients. PPVI reduced peak‐to‐peak pulmonary valve gradient from 43 (IQR 28‐60) mmHg to 16 (IQR 14‐22) mmHg (P < 0.001). Periprocedural complications occurred in two (8%) patients (tricuspid valve damage, pulmonary artery perforation). Over a median follow‐up of 43 (IQR 18‐58) months all patients were alive. Only two (8%) required re‐operation and two (8%) developed stent fractures (one of them had not undergone pre‐stenting). NYHA functional class improved significantly, with 20 (80%) patients in NYHA class I on follow‐up.Conclusions: PPVI with Medtronic Melody or Edwards Sapien valve conduits is safe and provides effective relief from right ventricular outflow tract obstruction or pulmonary regurgitation.


  • Open Access

    Diagnostic accuracy of coronary opacification derived from coronary computed tomography angiography to detect ischemia: first validation versus single-photon emission computed tomography

    by Dominik C. Benz, Fran Mikulicic, Christoph Gräni, Marvin Grossmann, Andreas A. Giannopoulos, Michael Messerli, Catherine Gebhard, Oliver Gaemperli, Ronny R. Buechel, Philipp A. Kaufmann, et al.

    Estimation of functional relevance of a coronary stenosis by fractional flow reserve (FFR) from coronary computed tomography angiography (CCTA) has recently provided encouraging results. Due to its limited availability, the corrected contrast opacification (CCO) decrease and the transluminal attenuation gradient (TAG) were suggested as less complex alternatives. The aim of the present study was to assess the accuracy of CCO decrease and TAG to predict ischemia as assessed by single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI). This retrospective study included 72 patients who underwent hybrid CCTA/SPECT MPI with at least one coronary artery stenosis. Of 127 vessels with a coronary stenosis in CCTA, 38 (30%) were causing ischemia in its subtending myocardium. The area under the curve (AUC) for CCO decrease to predict ischemia was 0.707 with sensitivity, specificity, negative predictive value, positive predictive value, and accuracy of 74, 64, 85, 47, and 67%, respectively. For TAG, the AUC was 0.469. CCTA-derived CCO decrease but not TAG predicts ischemia in SPECT MPI. The negative predictive value of CCO decrease of 85% may confer clinical implications in the diagnostic work-up of patients with a coronary stenosis.


  • Historical Account Cardiology

    by Oliver Gaemperli, Tobias A. Fuchs, Thomas F. Lüscher

  • The right timing for post-ischemic stunning

    by Dominik C. Benz, Oliver Gaemperli


  • A low-dose and an ultra-low-dose contrast agent protocol for coronary CT angiography in a clinical setting: quantitative and qualitative comparison to a standard dose protocol

    by Dominik C Benz, Christoph Gräni, Beatrice Hirt Moch, Fran Mikulicic, Jan Vontobel, Tobias A Fuchs, Julia Stehli, Olivier F Clerc, Mathias Possner, Aju P Pazhenkottil, et al.

    Objective:To evaluate the impact of a low-dose (LD) and an ultra-LD (ULD) contrast protocol for coronary CT angiography on qualitative and quantitative image parameters in a clinical setting.Methods:We scanned 120 consecutive patients with a 256-slice CT scanner applying a LD (60 patients, 35–55 ml) or ULD (60 patients, 25–45 ml) contrast protocol adapted to the body mass index. Visually assessed image quality and attenuation measured in each coronary segment were retrospectively compared in 20 consecutive patients scanned with a normal-dose (ND, 40–105 ml) contrast protocol.Results:Visually assessed image quality did not differ significantly among protocols. By contrast, attenuation obtained from the ULD protocol (median contrast volume 35 ml) differed significantly from the LD (median 45 ml) and ND (median 70 ml) protocols in the coronary segments (316 ± 52 vs 363 ± 60 and 359 ± 52 HU, p < 0.001). Attenuation did not differ significantly between the LD and ND protocol. The proportion of patients with in...


  • TCT-297 Percutaneous Coronary Intervention of Chronic Total Occlusions in Patients with Low Left Ventricular Ejection Fraction

    by Alfredo Galassi, Marouane Boukhris, Zied Belhadj, Lobna Laaroussi, Islam Ghanem, Davide Tomasello, Aurel Toma, Oliver Gaemperli, Thomas Luscher, Kambis Mashayekhi

  • Open Access

    Changes in serum biomarker profiles after percutaneous mitral valve repair with the MitraClip system

    by Ji-Na Yoon, Antonio H. Frangieh, Adrian Attinger-Toller, Christiane Gruner, Felix C. Tanner, Maurizio Taramasso, Roberto Corti, Thomas F. Lüscher, Frank Ruschitzka, Dominique Bettex, et al.

    Mitral regurgitation (MR) is one of the most common valvular diseases. Percu-taneous mitral valve repair with the MitraClipTM system is a novel percutaneous mitral valve repair (PMVR) technique for high-surgical-risk patients. However, the effect of PMVR on cir-culating cardiac or inflammatory biomarkers and their association with individual functional, echocardiographic and clinical outcomes is poorly investigated. A group of 144 patients with functional or degenerative MR (age, 75 ± 11 years; 41% females) underwent PMVR with the MitraClip system at the University Heart Center Zu-rich. Serum biomarkers as N-terminal pro-B-type natriuretic peptide (NT-proBNP), C-reactive protein (CRP) and creatinine were obtained from venous sampling at baseline and follow-up of 3-6 months. Median NT-proBNP decreased insignificantly from 2,942 (IQR 1,596-5,722) to 2,739 (IQR 1,440-4,296) ng/L, p = 0.21. NT-proBNP changes did not correlate with baseline left ventricular (LV) ejection fraction or LV dimensions, with New York Heart Association class on follow-up, or with clinical events on follow-up. CRP levels reached a peak on the third postoperative day at 34.0 mg/L with a subsequent slow decrease over the ensuing days. Despite successful PMVR, NT-proBNP remain fairly unchanged on follow-up and changes in NT-proBNP levels are poor predictors of functional improvement or clinical outcome after MitraClip treatment.